China, AstraZeneca

AstraZeneca’s China business under spotlight amid fraud case
AstraZeneca's (NASDAQ:AZN) selloff on Tuesday in response to reports that the company is facing a fraud investigation in China highlights how much value the Anglo-Swedish pharma giant has attached to the country,
AstraZeneca stock tanks over fears of expanding China fraud probe
AstraZeneca’s stock price dropped by 8.4% during Tuesday’s trading in London after a report fueled fears of a potentially escalating insurance fraud investigation in China. | AstraZeneca’s stock price dropped by 8.
Pharma Giant AstraZeneca Says China Chief Under Investigation
The head of multinational pharmaceutical giant AstraZeneca's China arm is under investigation in the country, the firm said.
AstraZeneca falls as fraud investigation reportedly expands in China (update)
An insurance fraud investigation linked to AstraZeneca (AZN) expands in China involving dozens of senior executives. Read more here.
Report finds China targeted AstraZeneca in fraud probe over cancer treatment
The pharmaceutical giant, whose China chief is now under investigation, was previously at the centre of insurance scam cases, report says.
TOP NEWS: AstraZeneca pledges to assist in China probe as shares slide
AstraZeneca PLC on Tuesday took the rare step of addressing a sharp fall in the company's share price. Shares in the Cambridge-based pharmaceuticals company slumped 8.2% to 10,138.10 pence each in London.
AstraZeneca Falls Most Since 2020 as China Probe Fears Mount
AstraZeneca Plc shares plunged in London, erasing about £14 billion ($18 billion) of market value, amid escalating concerns over a Chinese probe into the UK drugmaker.Most Read from BloombergFrom Housing to Immigration,
AstraZeneca shares fall on report of potential China probe fallout
AstraZeneca shares recorded their biggest one-day drop since March 2020 on Tuesday following a report that dozens of senior executives at its China unit could be implicated in the largest insurance fraud case in the country's pharma sector in years.
AstraZeneca fraud investigation expands in China
A fraud investigation linked to AstraZeneca (NASDAQ:AZN) has expanded to several government agencies, implicating dozens of senior executives at the company as of last week, Shanghai-based business news outlet Yicai reported Tuesday,
Investopedia on MSN3h
AstraZeneca Shares Slide As Execs in China Face Fraud Investigation
AstraZeneca shares declined Tuesday after reports that senior executives in China were potentially implicated in an ...
AstraZeneca’s Stock Drop Overreaction: Buy Rating Amid China Investigation Concerns
Analyst Etzer Darout of BMO Capital maintained a Buy rating on AstraZeneca (AZN – Research Report), retaining the price target of $89.00.
Why Is AstraZeneca Stock Sinking On Tuesday?
Chinese authorities detained AstraZeneca employees amid a probe into data privacy breaches and unlicensed drug sales, stock ...
AstraZeneca says experimental obesity pill safe in early-stage trial
AstraZeneca said on Monday its experimental weight-loss pill, licensed from China's Eccogene, was safe and tolerable in an ...
STAT1d
Probe of AstraZeneca executive in China raises questions about company’s tactics
China's investigation of AstraZeneca's top executive in the country is raising questions about the company's tactics there.